AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03092479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Intervention
Description: Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
Study NCT01578057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tasimelteon
Description: 20mg, once
Study NCT01578057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: 0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
Study NCT01578057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo tasimelteon
Description: once
Study NCT01578057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ethanol
Description: A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
Study NCT00822484 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095
Study NCT00822484 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT05904184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoxy resin-based sealers (ERS)
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Epoxy resin-based sealers.
Study NCT05904184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium silicate-based sealers (CSS)
Description: All teeth received one-visit endodontic treatment according to the treatment protocol of the Vietnamese Ministry of Health with the support of three-dimensional imaging equipment and an endodontic machine. After root canal preparation, obturation was performed using Calcium silicate-based sealers.
Study NCT01349686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diet
Description: Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
Study NCT01349686 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fasting
Description: No intake of fluids during labour.
Study NCT02598518 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrating Combined Therapies
Description: Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
Study NCT02598518 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
Study NCT04149639 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NeuroQ
Description: Supplement includes phosphatidylserine, coffee fruit, curcumin, ginkgo, gotu kola, and propolis active ingredients inside a veggie capsule.
Study NCT00695240 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)
Description: Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
Study NCT00946881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST 11 -mediated -VTP
Description: The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
Study NCT01404871 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: duloxetine
Description: oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
Study NCT04443088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: INV-1120
Description: INV-1120 is an investigational selective and potent small molecule indicated for the treatment of solid malignancies including, but not limited to colorectal, breast, pancreatic, lung and liver cancers.
Study NCT04443088 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as a dose of 200 mg on Day 1 of each 3-week treatment cycle.
Study NCT01182337 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intradiscal rhGDF-5
Description: The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
Study NCT01182337 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
Study NCT03151252 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cytobrush
Description: During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
Study NCT01240148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3161
Description: Single dose, intradermal injection
Study NCT01240148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Single dose, intradermal injection
Study NCT01240148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD3161 Placebo
Study NCT03060330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Laparoscopic Ventral Mesh Rectopexy
Description: This group will undergo modified laparoscopic ventral mesh rectopexy alone
Study NCT03060330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection
Description: This group will undergo modified laparoscopic ventral mesh rectopexy combined with modified stapled trans-anal rectal resection
Study NCT04101760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long-acting granulocyte colony stimulating factor
Description: Patients will accept long-acting granulocyte colony stimulating factor at 48 hour after the chemotherapy
Study NCT04101760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Short-acting granulocyte colony stimulating factor
Description: Patients will accept short-acting granulocyte colony stimulating factor followed regular or prophylactic patterns
Study NCT03180827 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ovarian tissue biopsy
Description: ovarian tissue biopsy during general anesthesia
Study NCT00328965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lacidipine
Description: Lacidipine 2, 4, 6mg
Study NCT01522625 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil fumarate 300mg per day
Description: tenofovir disoproxil fumarate 300mg per day for 3 years
Study NCT04422431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bis-Choline Tetrathiomolybdate
Description: Participants will be initiated at 15 milligrams once daily, then the dose will be increased to 30 milligrams once daily at Week 6.
Study NCT01533077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet® 100/25 mg
Description: immediate-release levodopa/carbidopa 100/25 (single-dose).
Study NCT00781274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MP-424
Description: 750 mg every 8 hours for 12 weeks
Study NCT00781274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 600 - 1000 mg/day based on body weight for 24 weeks
Study NCT00781274 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Alfa-2b
Description: 1.5 mcg/kg/week for 24 weeks
Study NCT01218243 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: needle
Description: For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Study NCT01218243 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: needle
Description: For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
Study NCT00807170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474 (Vandetanib)
Description: 100 mg as a once daily oral dose, 21 days
Study NCT00807170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiotherapy (WBRT)
Study NCT01717820 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Freeze-dried whole-grape powder
Description: Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
Study NCT01346982 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silimarine
Description: darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
Study NCT01522625 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, identical to TDF in appearance, once daily for 3years
Study NCT00567541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Battery Powered Microneuromodulator (BBPM)
Description: The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
Study NCT02779998 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non invasive ventilation
Description: non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
Study NCT02779998 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard oxygen therapy with facial mask
Study NCT04421261 — intervention group
Intervention type: DEVICE
Intervention: Air-Q Self Pressurized Airway Device with Blocker
Description: used in low risk adult females undergoing elective surgeries
Study NCT04421261 — intervention group
Intervention type: DEVICE
Intervention: Proseal Laryngeal Mask Airway
Description: used in low risk adult female patients undergoing elective surgeries
Study NCT02178423 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound for diagnosis of CVC position in children
Description: Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
Study NCT00807170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: 200 mg as a once daily oral dose, 21 days
Study NCT05372146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GSV radiofrequency ablation with concomitant phlebectomy
Description: Radiofrequency ablation with concomitant phlebectomy
Study NCT05372146 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GSV radiofrequency ablation with concomitant phlebectomy
Description: Radiofrequency ablation with concomitant phlebectomy
Study NCT00214331 — intervention group
Intervention type: DRUG
Intervention: ciprofloxacin
Description: ciprofloxacin 500 mg twice a day for five doses.
Study NCT00214331 — intervention group
Intervention type: DRUG
Intervention: azithromycin
Description: azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
Study NCT00214331 — intervention group
Intervention type: DRUG
Intervention: gentamicin
Description: a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
Study NCT04594174 — intervention group
Intervention type: PROCEDURE
Intervention: Fluid administration
Description: Patients will be treated in accordance with the criteria of the responsible physician and the hemodynamic data obtained with the Mostcareup monitor will be recorded and used for decision-making according to the hemodynamic management protocols of each center.~If the patient has a PPV ≥ 14%, for 3 minutes and a MAP \<65 mm Hg or a Systolic Blood Pressure \<90 mm Hg, a bolus volume load of 3 ml / kg weight of a balanced crystalloid solution in a time of 10 minutes36,37. The start of the volume charge (T1) will be noted by an event mark on the MostCareup monitor. The end of the volume charge (T2) will be noted by an event mark on the MostCareup monitor. Five minutes after the completion of the volume charge a new event will be marked on the MostCare monitor (T3). Both brands will serve as a reference for the analysis of hemodynamic data. Patients will be considered responders to the administration of fluids if the cardiac index (CI) increase.
Study NCT00468078 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: 10min acquisition, 90min after injection of F-18 FPCIT
Study NCT00468078 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PET/CT
Description: 10min acquisition, 90min after injection of F-18 FPCIT
Study NCT00468078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 FPCIT
Description: 5mCi, intravenous injection
Study NCT00468078 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 FPCIT
Description: 5mCi, intravenous injection
Study NCT04626752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T
Description: Volunteers will be treated with BCMA CAR-T cells
Study NCT04626752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 25mg/㎡ for D-4、D-3 and D-2
Study NCT04626752 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 500mg/㎡ for D-3 and D-2
Study NCT01362465 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy
Description: Implanting device to measure delays between paced chambers in heart failure patients.
Study NCT04439773 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: the control group will be given the same volume of saline.
Study NCT04439773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: the experimental group will be given 1-1.5mg/kg lidocaine and then 2mg/kg/h
Study NCT04289506 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mRNA expression
Description: The primary objective is the external validation of our filed patent-claims panels of mRNA biomarkers, which in the inflammatory and SIRS/Sepsis panels have better discriminatory properties than any other published biomarker panel for detecting individuals with severe inflammation and differentiating infectious and non-infectious origin of organ failure (Sepsis/SIRS).
Study NCT04284514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AKB-9778 Ophthalmic Solution
Description: AKB-9778 Ophthalmic Solution
Study NCT04284514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ophthalmic Solution
Description: Matched vehicle-control
Study NCT03130114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
Study NCT03130114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
Study NCT00781521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ofloxacin otic solution 0.3%
Description: ofloxacin otic solution 0.3% instilled twice a day for seven days
Study NCT04076670 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological intervention for family caregivers of patients at the end of life
Description: The intervention protocol is a structured programme within the framework of counselling, that aims to reduce anxiety and depression symptoms, as well as symptoms of burden (overburden).
Study NCT02939014 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab vedotin IV infusion
Study NCT01252875 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Target : 100 mg/dL (+/-10 mg/dL)
Description: Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
Study NCT01252875 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: 70 mg/dL
Description: Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
Study NCT00876018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Description: Fortified nutritional powder
Study NCT00876018 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Un-fortified nutritional powder
Study NCT02480218 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological test battery
Description: Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
Study NCT01302236 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone
Description: 50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
Study NCT00521755 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Seraffix LTB
Description: laser soldering for soft tissue wounds
Study NCT03113266 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody toripalimab
Description: humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
Study NCT02545855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula therapy
Description: All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
Study NCT02545855 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home oxygen therapy (HOT)
Description: All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.